Merriam-Webster defines biotechnology as the manipulation (as through genetic engineering) of living organisms or their components to produce useful usually commercial products (as pest resistant crops, new bacterial strains, or novel pharmaceuticals). Although this definition could broadly cover thousands of years of agriculture and animal breeding, the term biotechnology (often abbreviated as biotech) usually means the gene engineering technology that revolutionized the biological sciences starting with Cohen and Boyers demonstration of DNA cloning in their Stanford lab in 1973.

Since the first DNA cloning experiments over 40 years ago, genetic engineering techniques have developed to create engineered biological molecules, genetically designed microorganisms and cells, ways to find new genes and figure out how they work, and even transgenic animals and plants. In the midst of this bioengineering revolution, commercial applications exploded, and an industry developed around techniques like gene cloning, directed mutagenesis, DNA sequencing, RNA interference, biomolecule labeling and detection, and nucleic acid amplification.

The biotech industry broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas like the industrial production of chemicals and bioremediation, the use in these areas is still specialized and limited. On the other hand, the medical and agricultural industries have each undergone a biotech revolution with newand often controversial research efforts, development programs, and business strategies to discover, alter, or produce novel biomolecules and organisms using bioengineering.

Biotechnology introduced a whole new approach to drug development that did not easily integrate into the chemically-focused approach most of the established pharmaceutical companies were using. This shift precipitated a rash of start-up companies starting with the founding of Cetus (now part of Novartis Diagnostics) and Genentech in the mid-1970s.

Since there was an established venture capital community for the high-tech industry in Silicon Valley, many of the early biotechnology companies also clustered in the San Francisco Bay Area. Over the years, several hundreds of start-up companies have been founded and hot-spots have also developed in the US around Seattle, San Diego, North Carolina's Research Triangle Park, Boston, and Philadelphia, as well as a number of international locations including areas around Berlin, Heidelberg, and Munich in Germany, Oxford and Cambridge in the UK, and the Medicon Valley in eastern Denmark and southern Sweden.

Medical biotech, with revenues exceeding $150 billion annually, receives the bulk of biotech investment and research dollars. Even the term biotech is often used synonymously with this segment. This part of biotech constellates around the drug discovery "pipeline" that starts with basic research to identify genes or proteins associated with particular diseases which could be used as drug targets and diagnostic markers. Once a new gene or protein target is found, thousands of chemicals are screened to find potential drugs that affect the target.

The chemicals that look like they might work as drugs (sometimes known as "hits") then need to be optimized, checked for toxic side effects, and, finally, tested in clinical trials.

Biotech has been instrumental in the initial drug discovery and screening stages. Most major pharmaceutical companies have active target-discovery research programs heavily reliant on biotechnology, and smaller new companies such as Exelixis, BioMarin Pharmaceuticals, and Cephalon do focused drug discovery and development often using unique proprietary techniques. In addition to direct drug development, there are companies like Abbott Diagnostics and Becton-Dickenson that are looking for ways to use new disease-related genes to create new clinical diagnostics.

A lot of these tests identify the most responsive patients for new drugs coming into the market. Also, supporting research for new drugs is a long list of research and lab supply companies that provide basic kits, reagents, and equipment. For example, companies such as Life Technologies, Thermo-Fisher, Promega and a host of others provide lab tools and equipment for bioscience research, and companies such as Molecular Devices and DiscoveRx provide specially engineered cells and detection systems for screening potential new drugs.

The same biotechnology used for drug development can also improve agricultural and food products. However, unlike with pharmaceuticals, genetic engineering did not generate a rash of new ag-biotech start-ups. The difference may be that, despite the technological leap forward, biotech did not fundamentally change the nature of the agricultural industry. Manipulating crops and livestock to optimize genetics to enhance utility and improve yields has been going on for thousands of years. In a way, bioengineering just provides a convenient new method.

Established agricultural companies, such as Dow and Monsanto, simply integrated biotech into their R&D programs.

Most of the focus on ag-biotech is on crop improvement, which, as a business, has been quite successful. Since the first genetically modified corn was introduced in 1994, transgenic crop staples such as wheat, soybean, and tomatoes have become the norm. Now, more than 90% of US-grown corn, soybeans, and cotton are bioengineered. Although lagging behind bioengineered plants, use of biotechnology for farm animal improvement is also pretty prevalent.

Remember Dolly, the first cloned sheep? That was in 1996. Now animal cloning is common, and it's clear transgenic farm animals are on the immediate horizon based on headlines highlighting recent developments on the Federation of Animal Societies' website. Although genetically modified organisms (GMOs) have generated a lot of controversy in recent years, ag-biotech has become pretty well established. According to the 2011 International Service for the Acquisition of Agri-biotech Applications' (ISAAA) 2011 report, 160 million hectares of GMO crops were planted in 2011 with sales of over $160 billion in engineered grain.

Original post:
Biotechnology and the Biotech Industry

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer.

The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects.

CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models.

Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.

CDRDs Head of Biologics Dr. Ismael Samudio commented, This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics technology and help bring new therapeutic treatments to market.

It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.

About Novelogics Biotechnology, Inc.

Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind we want to create better cancer treatments. http://www.novelogics.com

Novelogics Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

About The Centre for Drug Research and Development (CDRD)

CDRD is Canadas national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. Canadas Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). http://www.cdrd.ca

Originally posted here:
Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment - Business Wire (press release)

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Link:
NAS Issues Report on Preparing for Future Products of Biotechnology - JD Supra (press release)

China will evaluate eight pending U.S. agricultural biotechnology product applications by the end of May, potentially opening the door for sales by Dow AgroSciences, DuPont Pioneer, Monsanto, and Syngenta.

China agreed to conduct the evaluations as part of an agreement unveiled by the White House on May 12. The two countries reached the trade deal after a meeting in April between U.S. President Donald J. Trump and Chinese President Xi Jinping.

U.S. officials have prodded China for years to speed up its lengthy process for deciding whether to approve the import of new genetically modified (GM) crops. It typically takes six years to win Chinese clearance of a GM variety, twice as long as other major nations take.

Under the new deal, Chinas National Biosafety Committee will meet by the end of May to assess the safety of eight products made by four major U.S. agrochemical companies.

Dow AgroSciences is seeking approval for its corn and soybean seeds, while Syngenta and DuPont Pioneer have each applied to sell a GM corn variety in China. Monsanto makes four of the products pending approval, including herbicide-tolerant corn, soybeans, and two alfalfa varieties that have been under review for nearly six years.

The Biotechnology Innovation Organization (BIO), an industry trade group, wants to make sure China lives up to its commitment.

The ultimate test of success will be for China to follow its process and quickly approve the eight pending biotechnology applications and establish a synchronized, timely, and predictable process going forward, says Joseph Damond, senior vice president for international affairs at BIO.

The rest is here:
China agrees to review US biotechnology applications - Chemical & Engineering News

Mar 16, 2017 (LBO) Sri Lankas cabinet has agreed to establish the Biotechnology Innovation Park in the Nanotechnology Park in Pitipana, Homagama as a public-private partnership project.

This years budget allocated 100 million rupees for the establishment of this facility which will provide facilities mainly for companies engaged in the pharmaceutical industry and genomics.

Apart from the land, the government will also allocate utilities such as electricity and water for the proposed facility.

Global market for biotechnology is estimated at over 453 billion US dollars in 2016 with an annual growth of over 10 percent.

In 2013, Sri Lankas first ever Nanotechnology and Science Park was commissioned in Homagama with the government investing over 2 billion rupees and six private companies cumulatively investing 310 million rupees.

Potential Sectors for Sri Lankan Biotechnology Industry Development

Enzyme: food, detergent, garment etc. Synthetic biology Pharmaceutical: Vaccines( including recombinant), anti-venom, antibiotics, herbal product drug delivery mechanisms etc. Medical diagnostics : Genomics, regenerative medicine etc. Tissue engineering : production of cell lines Bioinformatics Clinical trails Bioenergy Neutraceuticals and therapeutics Bio-products : bio-fertilizer, bio-pesticides etc Marine biotechnology : medicinal, food, chemical Environmental biotechnology : waste management Agriculture Biotechnology : crop improvement molecular breeding, biotech crops etc.

See the original post:
Sri Lanka wants Rs100mn Biotechnology Park in Homagama ... - Lanka Business Online

Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services.[1] From its inception, biotechnology has maintained a close relationship with society. Although now most often associated with the development of drugs, historically biotechnology has been principally associated with food, addressing such issues as malnutrition and famine. The history of biotechnology begins with zymotechnology, which commenced with a focus on brewing techniques for beer. By World War I, however, zymotechnology would expand to tackle larger industrial issues, and the potential of industrial fermentation gave rise to biotechnology. However, both the single-cell protein and gasohol projects failed to progress due to varying issues including public resistance, a changing economic scene, and shifts in political power.

Yet the formation of a new field, genetic engineering, would soon bring biotechnology to the forefront of science in society, and the intimate relationship between the scientific community, the public, and the government would ensue. These debates gained exposure in 1975 at the Asilomar Conference, where Joshua Lederberg was the most outspoken supporter for this emerging field in biotechnology. By as early as 1978, with the development of synthetic human insulin, Lederberg's claims would prove valid, and the biotechnology industry grew rapidly. Each new scientific advance became a media event designed to capture public support, and by the 1980s, biotechnology grew into a promising real industry. In 1988, only five proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA), but this number would skyrocket to over 125 by the end of the 1990s.

The field of genetic engineering remains a heated topic of discussion in today's society with the advent of gene therapy, stem cell research, cloning, and genetically modified food. While it seems only natural nowadays to link pharmaceutical drugs as solutions to health and societal problems, this relationship of biotechnology serving social needs began centuries ago.

Biotechnology arose from the field of zymotechnology or zymurgy, which began as a search for a better understanding of industrial fermentation, particularly beer. Beer was an important industrial, and not just social, commodity. In late 19th-century Germany, brewing contributed as much to the gross national product as steel, and taxes on alcohol proved to be significant sources of revenue to the government.[2] In the 1860s, institutes and remunerative consultancies were dedicated to the technology of brewing. The most famous was the private Carlsberg Institute, founded in 1875, which employed Emil Christian Hansen, who pioneered the pure yeast process for the reliable production of consistent beer. Less well known were private consultancies that advised the brewing industry. One of these, the Zymotechnic Institute, was established in Chicago by the German-born chemist John Ewald Siebel.

The heyday and expansion of zymotechnology came in World War I in response to industrial needs to support the war. Max Delbrck grew yeast on an immense scale during the war to meet 60 percent of Germany's animal feed needs.[2] Compounds of another fermentation product, lactic acid, made up for a lack of hydraulic fluid, glycerol. On the Allied side the Russian chemist Chaim Weizmann used starch to eliminate Britain's shortage of acetone, a key raw material for cordite, by fermenting maize to acetone.[3] The industrial potential of fermentation was outgrowing its traditional home in brewing, and "zymotechnology" soon gave way to "biotechnology."

With food shortages spreading and resources fading, some dreamed of a new industrial solution. The Hungarian Kroly Ereky coined the word "biotechnology" in Hungary during 1919 to describe a technology based on converting raw materials into a more useful product. He built a slaughterhouse for a thousand pigs and also a fattening farm with space for 50,000 pigs, raising over 100,000 pigs a year. The enterprise was enormous, becoming one of the largest and most profitable meat and fat operations in the world. In a book entitled Biotechnologie, Ereky further developed a theme that would be reiterated through the 20th century: biotechnology could provide solutions to societal crises, such as food and energy shortages. For Ereky, the term "biotechnologie" indicated the process by which raw materials could be biologically upgraded into socially useful products.[4]

This catchword spread quickly after the First World War, as "biotechnology" entered German dictionaries and was taken up abroad by business-hungry private consultancies as far away as the United States. In Chicago, for example, the coming of prohibition at the end of World War I encouraged biological industries to create opportunities for new fermentation products, in particular a market for nonalcoholic drinks. Emil Siebel, the son of the founder of the Zymotechnic Institute, broke away from his father's company to establish his own called the "Bureau of Biotechnology," which specifically offered expertise in fermented nonalcoholic drinks.[1]

The belief that the needs of an industrial society could be met by fermenting agricultural waste was an important ingredient of the "chemurgic movement."[4] Fermentation-based processes generated products of ever-growing utility. In the 1940s, penicillin was the most dramatic. While it was discovered in England, it was produced industrially in the U.S. using a deep fermentation process originally developed in Peoria, Illinois.[5] The enormous profits and the public expectations penicillin engendered caused a radical shift in the standing of the pharmaceutical industry. Doctors used the phrase "miracle drug", and the historian of its wartime use, David Adams, has suggested that to the public penicillin represented the perfect health that went together with the car and the dream house of wartime American advertising.[2] Beginning in the 1950s, fermentation technology also became advanced enough to produce steroids on industrially significant scales.[6] Of particular importance was the improved semisynthesis of cortisone which simplified the old 31 step synthesis to 11 steps.[7] This advance was estimated to reduce the cost of the drug by 70%, making the medicine inexpensive and available.[8] Today biotechnology still plays a central role in the production of these compounds and likely will for years to come.[9][10]

Even greater expectations of biotechnology were raised during the 1960s by a process that grew single-cell protein. When the so-called protein gap threatened world hunger, producing food locally by growing it from waste seemed to offer a solution. It was the possibilities of growing microorganisms on oil that captured the imagination of scientists, policy makers, and commerce.[1] Major companies such as British Petroleum (BP) staked their futures on it. In 1962, BP built a pilot plant at Cap de Lavera in Southern France to publicize its product, Toprina.[1] Initial research work at Lavera was done by Alfred Champagnat,[11] In 1963, construction started on BP's second pilot plant at Grangemouth Oil Refinery in Britain.[11]

As there was no well-accepted term to describe the new foods, in 1966 the term "single-cell protein" (SCP) was coined at MIT to provide an acceptable and exciting new title, avoiding the unpleasant connotations of microbial or bacterial.[1]

The "food from oil" idea became quite popular by the 1970s, when facilities for growing yeast fed by n-paraffins were built in a number of countries. The Soviets were particularly enthusiastic, opening large "BVK" (belkovo-vitaminny kontsentrat, i.e., "protein-vitamin concentrate") plants next to their oil refineries in Kstovo (1973) [12][13] and Kirishi (1974).[citation needed]

By the late 1970s, however, the cultural climate had completely changed, as the growth in SCP interest had taken place against a shifting economic and cultural scene (136). First, the price of oil rose catastrophically in 1974, so that its cost per barrel was five times greater than it had been two years earlier. Second, despite continuing hunger around the world, anticipated demand also began to shift from humans to animals. The program had begun with the vision of growing food for Third World people, yet the product was instead launched as an animal food for the developed world. The rapidly rising demand for animal feed made that market appear economically more attractive. The ultimate downfall of the SCP project, however, came from public resistance.[1]

This was particularly vocal in Japan, where production came closest to fruition. For all their enthusiasm for innovation and traditional interest in microbiologically produced foods, the Japanese were the first to ban the production of single-cell proteins. The Japanese ultimately were unable to separate the idea of their new "natural" foods from the far from natural connotation of oil.[1] These arguments were made against a background of suspicion of heavy industry in which anxiety over minute traces of petroleum was expressed. Thus, public resistance to an unnatural product led to the end of the SCP project as an attempt to solve world hunger.

Also, in 1989 in the USSR, the public environmental concerns made the government decide to close down (or convert to different technologies) all 8 paraffin-fed-yeast plants that the Soviet Ministry of Microbiological Industry had by that time.[citation needed]

In the late 1970s, biotechnology offered another possible solution to a societal crisis. The escalation in the price of oil in 1974 increased the cost of the Western world's energy tenfold.[1] In response, the U.S. government promoted the production of gasohol, gasoline with 10 percent alcohol added, as an answer to the energy crisis.[2] In 1979, when the Soviet Union sent troops to Afghanistan, the Carter administration cut off its supplies to agricultural produce in retaliation, creating a surplus of agriculture in the U.S. As a result, fermenting the agricultural surpluses to synthesize fuel seemed to be an economical solution to the shortage of oil threatened by the Iran-Iraq war. Before the new direction could be taken, however, the political wind changed again: the Reagan administration came to power in January 1981 and, with the declining oil prices of the 1980s, ended support for the gasohol industry before it was born.[1]

Biotechnology seemed to be the solution for major social problems, including world hunger and energy crises. In the 1960s, radical measures would be needed to meet world starvation, and biotechnology seemed to provide an answer. However, the solutions proved to be too expensive and socially unacceptable, and solving world hunger through SCP food was dismissed. In the 1970s, the food crisis was succeeded by the energy crisis, and here too, biotechnology seemed to provide an answer. But once again, costs proved prohibitive as oil prices slumped in the 1980s. Thus, in practice, the implications of biotechnology were not fully realized in these situations. But this would soon change with the rise of genetic engineering.

The origins of biotechnology culminated with the birth of genetic engineering. There were two key events that have come to be seen as scientific breakthroughs beginning the era that would unite genetics with biotechnology. One was the 1953 discovery of the structure of DNA, by Watson and Crick, and the other was the 1973 discovery by Cohen and Boyer of a recombinant DNA technique by which a section of DNA was cut from the plasmid of an E. coli bacterium and transferred into the DNA of another.[14] This approach could, in principle, enable bacteria to adopt the genes and produce proteins of other organisms, including humans. Popularly referred to as "genetic engineering," it came to be defined as the basis of new biotechnology.

Genetic engineering proved to be a topic that thrust biotechnology into the public scene, and the interaction between scientists, politicians, and the public defined the work that was accomplished in this area. Technical developments during this time were revolutionary and at times frightening. In December 1967, the first heart transplant by Christian Barnard reminded the public that the physical identity of a person was becoming increasingly problematic. While poetic imagination had always seen the heart at the center of the soul, now there was the prospect of individuals being defined by other people's hearts.[1] During the same month, Arthur Kornberg announced that he had managed to biochemically replicate a viral gene. "Life had been synthesized," said the head of the National Institutes of Health.[1] Genetic engineering was now on the scientific agenda, as it was becoming possible to identify genetic characteristics with diseases such as beta thalassemia and sickle-cell anemia.

Responses to scientific achievements were colored by cultural skepticism. Scientists and their expertise were looked upon with suspicion. In 1968, an immensely popular work, The Biological Time Bomb, was written by the British journalist Gordon Rattray Taylor. The author's preface saw Kornberg's discovery of replicating a viral gene as a route to lethal doomsday bugs. The publisher's blurb for the book warned that within ten years, "You may marry a semi-artificial man or womanchoose your children's sextune out painchange your memoriesand live to be 150 if the scientific revolution doesnt destroy us first."[1] The book ended with a chapter called "The Future If Any." While it is rare for current science to be represented in the movies, in this period of "Star Trek", science fiction and science fact seemed to be converging. "Cloning" became a popular word in the media. Woody Allen satirized the cloning of a person from a nose in his 1973 movie Sleeper, and cloning Adolf Hitler from surviving cells was the theme of the 1976 novel by Ira Levin, The Boys from Brazil.[1]

In response to these public concerns, scientists, industry, and governments increasingly linked the power of recombinant DNA to the immensely practical functions that biotechnology promised. One of the key scientific figures that attempted to highlight the promising aspects of genetic engineering was Joshua Lederberg, a Stanford professor and Nobel laureate. While in the 1960s "genetic engineering" described eugenics and work involving the manipulation of the human genome, Lederberg stressed research that would involve microbes instead.[1] Lederberg emphasized the importance of focusing on curing living people. Lederberg's 1963 paper, "Biological Future of Man" suggested that, while molecular biology might one day make it possible to change the human genotype, "what we have overlooked is euphenics, the engineering of human development."[1] Lederberg constructed the word "euphenics" to emphasize changing the phenotype after conception rather than the genotype which would affect future generations.

With the discovery of recombinant DNA by Cohen and Boyer in 1973, the idea that genetic engineering would have major human and societal consequences was born. In July 1974, a group of eminent molecular biologists headed by Paul Berg wrote to Science suggesting that the consequences of this work were so potentially destructive that there should be a pause until its implications had been thought through.[1] This suggestion was explored at a meeting in February 1975 at California's Monterey Peninsula, forever immortalized by the location, Asilomar. Its historic outcome was an unprecedented call for a halt in research until it could be regulated in such a way that the public need not be anxious, and it led to a 16-month moratorium until National Institutes of Health (NIH) guidelines were established.

Joshua Lederberg was the leading exception in emphasizing, as he had for years, the potential benefits. At Asilomar, in an atmosphere favoring control and regulation, he circulated a paper countering the pessimism and fears of misuses with the benefits conferred by successful use. He described "an early chance for a technology of untold importance for diagnostic and therapeutic medicine: the ready production of an unlimited variety of human proteins. Analogous applications may be foreseen in fermentation process for cheaply manufacturing essential nutrients, and in the improvement of microbes for the production of antibiotics and of special industrial chemicals."[1] In June 1976, the 16-month moratorium on research expired with the Director's Advisory Committee (DAC) publication of the NIH guidelines of good practice. They defined the risks of certain kinds of experiments and the appropriate physical conditions for their pursuit, as well as a list of things too dangerous to perform at all. Moreover, modified organisms were not to be tested outside the confines of a laboratory or allowed into the environment.[14]

Atypical as Lederberg was at Asilomar, his optimistic vision of genetic engineering would soon lead to the development of the biotechnology industry. Over the next two years, as public concern over the dangers of recombinant DNA research grew, so too did interest in its technical and practical applications. Curing genetic diseases remained in the realms of science fiction, but it appeared that producing human simple proteins could be good business. Insulin, one of the smaller, best characterized and understood proteins, had been used in treating type 1 diabetes for a half century. It had been extracted from animals in a chemically slightly different form from the human product. Yet, if one could produce synthetic human insulin, one could meet an existing demand with a product whose approval would be relatively easy to obtain from regulators. In the period 1975 to 1977, synthetic "human" insulin represented the aspirations for new products that could be made with the new biotechnology. Microbial production of synthetic human insulin was finally announced in September 1978 and was produced by a startup company, Genentech.[15] Although that company did not commercialize the product themselves, instead, it licensed the production method to Eli Lilly and Company. 1978 also saw the first application for a patent on a gene, the gene which produces human growth hormone, by the University of California, thus introducing the legal principle that genes could be patented. Since that filing, almost 20% of the more than 20,000 genes in the human DNA have been patented.[citation needed]

The radical shift in the connotation of "genetic engineering" from an emphasis on the inherited characteristics of people to the commercial production of proteins and therapeutic drugs was nurtured by Joshua Lederberg. His broad concerns since the 1960s had been stimulated by enthusiasm for science and its potential medical benefits. Countering calls for strict regulation, he expressed a vision of potential utility. Against a belief that new techniques would entail unmentionable and uncontrollable consequences for humanity and the environment, a growing consensus on the economic value of recombinant DNA emerged.[citation needed]

With ancestral roots in industrial microbiology that date back centuries, the new biotechnology industry grew rapidly beginning in the mid-1970s. Each new scientific advance became a media event designed to capture investment confidence and public support.[15] Although market expectations and social benefits of new products were frequently overstated, many people were prepared to see genetic engineering as the next great advance in technological progress. By the 1980s, biotechnology characterized a nascent real industry, providing titles for emerging trade organizations such as the Biotechnology Industry Organization (BIO).

The main focus of attention after insulin were the potential profit makers in the pharmaceutical industry: human growth hormone and what promised to be a miraculous cure for viral diseases, interferon. Cancer was a central target in the 1970s because increasingly the disease was linked to viruses.[14] By 1980, a new company, Biogen, had produced interferon through recombinant DNA. The emergence of interferon and the possibility of curing cancer raised money in the community for research and increased the enthusiasm of an otherwise uncertain and tentative society. Moreover, to the 1970s plight of cancer was added AIDS in the 1980s, offering an enormous potential market for a successful therapy, and more immediately, a market for diagnostic tests based on monoclonal antibodies.[16] By 1988, only five proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA): synthetic insulin, human growth hormone, hepatitis B vaccine, alpha-interferon, and tissue plasminogen activator (TPa), for lysis of blood clots. By the end of the 1990s, however, 125 more genetically engineered drugs would be approved.[16]

Genetic engineering also reached the agricultural front as well. There was tremendous progress since the market introduction of the genetically engineered Flavr Savr tomato in 1994.[16] Ernst and Young reported that in 1998, 30% of the U.S. soybean crop was expected to be from genetically engineered seeds. In 1998, about 30% of the US cotton and corn crops were also expected to be products of genetic engineering.[16]

Genetic engineering in biotechnology stimulated hopes for both therapeutic proteins, drugs and biological organisms themselves, such as seeds, pesticides, engineered yeasts, and modified human cells for treating genetic diseases. From the perspective of its commercial promoters, scientific breakthroughs, industrial commitment, and official support were finally coming together, and biotechnology became a normal part of business. No longer were the proponents for the economic and technological significance of biotechnology the iconoclasts.[1] Their message had finally become accepted and incorporated into the policies of governments and industry.

According to Burrill and Company, an industry investment bank, over $350 billion has been invested in biotech since the emergence of the industry, and global revenues rose from $23 billion in 2000 to more than $50 billion in 2005. The greatest growth has been in Latin America but all regions of the world have shown strong growth trends. By 2007 and into 2008, though, a downturn in the fortunes of biotech emerged, at least in the United Kingdom, as the result of declining investment in the face of failure of biotech pipelines to deliver and a consequent downturn in return on investment.[17]

Read this article:
History of biotechnology - Wikipedia

March 3, 2017 6:13am NASDAQ:IBB

From Taki Tsaklanos: Biotechnology stocks are breaking out. They have been consolidating for nearly 20 months. Investors lost interestand that is exactly what smart investors, in general, want to see in order to buy a market.

That is also how bull markets start: when nobody talks about it and only a minority of investors is buying it.

Now here it becomes interesting. InvestingHavens research team has closely followed biotechnology, and has written extensively about it last year. The red line throughout all articles was that smart investors are not in a hurry to buy biotech, but prefer to see which direction biotech would go. This is what was published on InvestingHaven until fall of last year:

Biotechnology Close To A Major Breakdown Level

Health Sector Testing All-Time Highs In 2016, Biotech A Buy After Breaking Out

Alert: Biotechnology and Health Sector Testing Long Time Support

Biotechnology Stocks Have News For Investors: It is Now or Never

In other words, on several occasions last year biotechnology stocks were ready to break down, but eventually they did not. The market refused to go lower, and that was a very important observation, which was shared with our readers: Biotechnology Stocks Refusing To Break Down

Then, something very interesting happened in January: Biotech And Health Care Stock Market Sector Showing Signs Of Life. That was the first sign that biotechnology stocks could go higher.

Today, they are attempting to break out.

The most interesting part was what InvestingHavens team wrote last year in April: Biotechnology Sentiment At Multi-Year Extremes. What Should Investors Do? Right at a time when a major breakout attempt in biotechnology stocks was at play, at a time when sentiment was extremely bullish, we wrote this:

What does all this mean to investors? Combining chart patterns with sentiment data is very useful for investors. We believe that a short term top has developed. Biotechnology needs to cool off a bit, which means a retracement is the most likely outcome for the coming weeks. The key is to watch how far the retracement will go: if prices remain within the existing pattern, above support, there is an opportunity for investors to buy the dips. As long as prices remain within the current chart pattern, it is not a good idea to short this market, unless you are a very short term oriented trader.

As a reminder, it was when IBB was trading at 280 points, in April last year, right before it fell 15 percent. Astute readers were very happy, and they keep on thanking us for our wise words.

Right now, biotechnology stocks are going through a serious attempt to break out from their 20-month consolidation period. If the 300 level in IBB holds for at least 5 consecutive days, biotech will go higher in the coming weeks and months.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was unchanged in premarket trading Friday. Year-to-date, IBB has gained 12.97%, versus a 6.59% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB Taki Tsaklanos

Categories: NASDAQ:IBB

Read the original:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB ... - ETF Daily News (blog)

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) plunged more than 25 percent following plans to modify the summary of product characteristics (SmPC) in its European Marketing Authorization Application (MAA) for its breast cancer drug neratinib.

The company now plans to restrict the intended population to patients initiating neratinib treatment within one year after completion of adjuvant trastuzumab therapy.

Earlier, the proposed indication was for the "extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab based therapy."

Puma submitted its neratinib MAA last summer.

During the regulators meeting, the timeline for Neratinib was discussed. Neratinib will likely be sequenced immediately after adjuvant trastuzumab. Furthermore, more benefits were observed in the subgroup of patients who received neratinib within one year from prior trastuzumab completion.

Related Link: Here's What To Expect Following Trump's Drug Pricing 'Robbery' Comments

In addition, data from the pivotal adjuvant trastuzumab trials suggest that patients are at higher risk of recurrence closer to completion of adjuvant trastuzumab, and the risk of recurrence may decrease over time.

Puma also noted that the Committee for Medicinal Products for Human Use (CHMP) is continuing to review Puma's MAA and has not yet made a final decision to recommend approval of the drug for the updated or any other indication and there is no guarantee when, if ever, the MAA will be approved.

Separately, Puma reported a wider loss for its fourth quarter. On a GAAP basis, Puma reported a net loss applicable to common stock of $72.7 million, or $2.04 per share, versus a net loss of $61.7 million, or $1.90 per share, a year ago.

Excluding items, the loss came in at $1.22 a share versus loss of $1.23 a share, last year. However, the loss was better than consensus loss estimate of $1.92 a share.

On December 31, 2016, Puma had cash and cash equivalents of $194.5 million and marketable securities of $35.0 million.

Shares of Puma closed Wednesdays trading at $38.05. In the pre-market hours Thursday, the stock plunged 26.41 percent to $28.

According to the verified Twitter account of TheStreet's senior columnist Adam Feuerstein, "Hedge funds that own $PBYI are screaming at sell side analysts to defend the stock."

TheStreet also published on its website a possible connection between Puma's movements and those of Roche Holding Ltd. (ADR) (OTC: RHHBY). Feuerstein and Martin Baccardax wrote: "The Roche AG (RHHBY) breast cancer drug Perjeta notched an important win in the closely followed 'Aphinity' clinical trial, promising to add billions of dollars in sales to the Swiss drugmaker's top line. Perjeta's success spells big trouble for Puma Biotechnology (PBYI), which could see its competeing, but still approved, breast cancer drug neratinib without any patients to treat."

At last check in Thursday's pre-market session, shares of Puma were down 26.54 percent at $27.95. ADR shares of Roche were up 5.75 percent at $32.30.

Posted-In: Biotech Earnings News Health Care FDA Movers Media Trading Ideas Best of Benzinga

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More here:
Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta Win - Benzinga

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Cellect Biotechnology Ltd. (Nasdaq: APOP) announced today positive final results from its clinical trial of ApoGraft in healthy donors. The studys primary objective was to validate the Company's propriety method of stem cell selection by going through the process of production and characterization with ApoGraft, and was conducted on samples obtained in collaboration with two leading medical centers in Israel, The Schneider Children's Medical Center and the Rambam Medical Center.

Cellects technology enables the use of stem cells for regenerative therapies by eliminating mature cells while leaving the stem cells unharmed using a natural process occurring in the human body, apoptosis (programed cell death), which orders cells to commit suicide. Cellects validated scientific platform, and the focus of its 7 families of patents, is that the apoptosis command destroys primarily mature cells, while stem cells remain alive and flourishing. This process allows for natural enrichment of stem cells, thus enabling stem cell-based therapies or transplantation to possess an abundance of quality stem cells with little to no risk of rejection or other complications, such as Graft versus Host Disease (GvHD).

The study included 104 healthy donors of blood stem cells. The samples (collected under approval of Helsinki committees) represented 5% of a graft used for transplantation into patients. The grafts were processed allowing stem cell production for transplantation with Cellects ApoGraft. The use of the ApoGraft resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

Dr. Yaron Pereg, Cellects Chief Development Officer, commented: These results from processing human stem cells for bone marrow transplantation using ApoGraft clearly demonstrated that Cellects proprietary platform could improve the outcome of stem cell transplantations in patients suffering from hematological malignancies.

Originally posted here:
Cellect Biotechnology (APOP) Announces Positive Results of Clinical Trial of ApoGraft - StreetInsider.com

NEW YORK, Feb. 20, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Biofuel Enzymes in US$ Thousand by the following Product Types: Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Read the full report: http://www.reportlinker.com/p04707128-summary/view-report.html

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 24 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Agrivida, Inc. - BASF SE - CLEA Technologies B.V

Read the full report: http://www.reportlinker.com/p04707128-summary/view-report.html

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Xylanase.............. I-3 Amylase.............. I-4 Cellulase.............. I-4 Others.............. I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Biofuel Enzymes: Delivering Productivity, Performance, and Environment Benefits in Biofuels Production II-1 Focus on Biofuels as the Future Energy Security Solution Drives Strong Demand for Biofuel Enzymes II-2 Factors Driving the Shift towards Bio-Fuels II-3 Table 1: Global Biofuels (Fuel Ethanol and Biodiesel) Market by Region/Country (2016 & 2020): Percentage Breakdown of Volume Consumption (in '000 Gallons) for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World (includes corresponding Graph/Chart) II-4

Table 2: Global Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016): Percentage Breakdown of Volume Consumption for Biodiesel and Fuel Ethanol (includes corresponding Graph/Chart)..............II-5 Expanding Role of Renewable Fuels in the Global Energy Mix II-5 Key Pollutants Present in Petroleum-based Fuel Emissions II-6 Hydrocarbons (HCs)..............II-6 Carbon Monoxide (CO)..............II-6 Oxides of Nitrogen (NOx)..............II-6 Particulate Matter (PM)..............II-6 Table 3: Global Energy Sector by Source (2016): Percentage Breakdown of Consumption for Coal, Natural Gas, Nuclear Energy, Petroleum and Renewables (includes corresponding Graph/Chart).............. II-7

Table 4: Global Renewable Energy Sector by Source (2016): Percentage Breakdown of Volume Supply for Biofuels (Liquid and Solid), Biogases, Geothermal, Hydro, Municipal Waste, Solar and Wind (includes corresponding Graph/Chart) II-7

Table 5: Global Primary Energy Sector by Region (2016): Percentage Breakdown for Energy Consumption for North America, Europe, Asia, Latin America, The Middle East and Africa (includes corresponding Graph/Chart) II-7 Superiority of Enzyme-based Production over Conventional Method Drives Widespread Adoption II-8 Global Market Outlook..............II-9 Developed Markets: Key Revenue Contributors II-9 Despite Slower Growth, Developing Countries Offer Huge Market Potential.............. II-10 Improving Economic Growth Encourage Optimistic Market Outlook II-10 Table 6: Global Real Per Capita GDP by Region (2015, 2020, 2025, and 2030): Projected Annual Growth Rate (%) for North America, Latin America, Europe, East Asia, Southeast Asia, South Asia, Oceania, Middle East, North Africa, and Sub-Saharan Africa (includes corresponding Graph/Chart) II-11 Competitive Landscape..............II-12 Leading Players in the Biofuel Enzymes Market II-12 Vendors Focus on Partnerships to Improve Prospects II-12

2. MARKET TRENDS, ISSUES & DRIVERS II-13 Growing Use of Biofuel Enzymes in Second Generation Bioethanol and Advanced Biodiesel Production Drive Market Growth II-13 Table 7: Global Second Generation Ethanol Production Capacity by Country/Region (2016): Percentage Breakdown of Installed Capacity for Brazil, Canada, China, Europe, US and Others (includes corresponding Graph/Chart) II-13 Expanding Footprint of Second-Generation Biofuels: An Important Opportunity Indicator II-14 First Generation Vs Second Generation Biofuels: A Snapshot II-14 Table 8: Global Advanced Biofuels Capacity by Type (2016): Percentage Breakdown of Installed Capacity for Advanced Biodiesel, Advanced Ethanol, and Others (includes corresponding Graph/Chart)..............II-15 Projected Growth in Cellulosic Biofuels Demand to Underpin Enzymes Sales.............. II-15 Cellulosic Biofuels Vs Conventional Biofuels and Petroleum II-15 Improving Economics of Cellulosic Biofuel Production Augur Well II-16 Switchgrass: Potential Feedstock in Advanced Biofuel Production II-16 Myriad Benefits Continue to Sustain Demand for Amylases in Fuel Ethanol Production..............II-16 New Enzyme Compounds to Drive Growth of Amylase Biofuel Enzyme Market.............. II-17 Bright Prospects for Cellulase Enzymes in Cellulosic Ethanol Production.............. II-17 Favorable Biofuel Blend Mandates & Blend Targets Offer Opportunities on a Platter..............II-17 Biofuel Blend Mandates & Blend Targets for Major Countries II-18 Enzymatic Production of Biodiesel from Low Quality Oils Gathers Steam.............. II-19 Increase in Algae-based Biofuel Production to Benefit Market Expansion.............. II-19 Innovative Technologies and Strategies Fuel Demand for Algal Fuel.............. II-19 Ongoing R&D Efforts to Strengthen Future Growth Prospects II-20 IBRL's Researchers Aim to Develop Cost-Effective Ethanol Production Process..............II-20 University of California Irvine to Develop Enzyme Processing VFD Technology.............. II-21 Fungal Species Exude Enzymes with Similar Functional Characteristics.............. II-21 Copenhagen Chemists Evaluate Role of LPMO Enzymes in Cellulose Breakdown..............II-21 Bioforsk Aims to Use Genetically Engineered Tobacco for Biofuels Production..............II-22 Researchers Exploit Mutated Fungus to Boost Production of Biofuel Enzymes.............. II-22 DOE-Funded Researchers Produce Structure & Functional Characterization of GH55 Enzyme Family II-22 NREL Researchers Develop Cellulase Enzyme from Bacterium II-23 Tokyo Researchers Study CBAP Enzyme Mechanism in Biofuel Production.............. II-23 Key Issues & Challenges Hampering Market Prospects for Biofuel & Biofuel Enzymes..............II-23 Growing Sales of Electric Vehicles II-24 Decline in Crude Oil Prices..............II-24 Widening Share of Natural Gas in the Energy Mix II-25

3. PRODUCT OVERVIEW.............. II-26 Biofuel Enzymes: An Introduction II-26 Biofuel Enzymes Vs Chemical Catalysts II-26 Benefits of Biofuel Enzymes..............II-26 Limitations of Biofuel Enzymes II-27 Limited Reproducibility..............II-27 Thermal Instability..............II-27 Low Catalytic Activity in Process Conditions II-27 Types of Biofuel Enzymes..............II-27 Xylanase.............. II-27 Amylase.............. II-28 Cellulase.............. II-28 Others.............. II-28 Proteases.............. II-28 Lipases.............. II-29

4. PRODUCT INNOVATIONS/INTRODUCTIONS II-30 DuPont Rolls Out OPTIMASH AD-100 II-30 Novozymes Introduces Fermax Enzyme Protease II-30 Novozymes Launches Avantec Amp II-30 Novozymes Introduces Liquozyme LpH II-30 TransBiodiesel Develops New Enzymatic Biodiesel Production Process.............. II-30 Novozymes Unveils Eversa..............II-30

5. RECENT INDUSTRY ACTIVITY..............II-31 Aemetis Signs License Agreement with Edeniq II-31 DuPont Industrial Biosciences Signs Supply Agreement with MIAVIT II-31 Novozymes to Establish New Enzyme Production Facility in India II-31 SRS International Teams Up with Biodiesel Experts International II-31 DuPont to Acquire Enzyme Technologies Business of Dyadic International.............. II-31 Du Pont to Supply Biofuel Enzymes to Quad County Corn Processors II-31 Novozymes Inks Supply Deal with St1 Biofuels II-32 Novozymes and Tactical Fabrication Collaborate with Viesel Fuel II-32 Iogen Develops New Drop-In Cellulosic Biofuels II-32 Compagnie des Levures Acquires Xylose Isomerase Technology from Butalco.............. II-32 Iogen Collaborates with Razen II-32

6. FOCUS ON SELECT PLAYERS..............II-33 AB Enzymes GmbH (Germany)..............II-33 Advanced Enzyme Technologies Ltd. (India) II-33 Agrivida, Inc. (USA)..............II-33 BASF SE (Germany).............. II-34 Verenium Corporation (Germany)..............II-34 CLEA Technologies B.V. (Netherlands) II-34 E. I. du Pont de Nemours and Company (USA) II-35 Enzyme Supplies Limited (UK)..............II-35 Iogen Corporation (Canada)..............II-35 Metgen Oy (Finland).............. II-36 NextCAT, Inc. (USA).............. II-36 Noor Enzymes Pvt. Ltd. (India) II-36 Novozymes A/S (Denmark)..............II-37 Royal DSM NV (Netherlands)..............II-37 TransBiodiesel Ltd. (Israel)..............II-37

7. GLOBAL MARKET PERSPECTIVE..............II-38 Table 9: World Recent Past, Present and Future Analysis for Biofuel Enzymes By Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-38

Table 10: World Historic Review for Biofuel Enzymes by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) II-39

Table 11: World 14-Year Perspective for Biofuel Enzymes by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-40

Table 12: World Recent Past, Present and Future Analysis for Biofuel Enzymes by Enzyme Type - Xylanase, Amylase, Cellulase and Others Markets Independently Analyzed with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-41

Table 13: World Historic Review for Biofuel Enzymes by Enzyme Type - Xylanase, Amylase, Cellulase and Others Markets Independently Analyzed with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-42

Table 14: World 14-Year Perspective for Biofuel Enzymes by Enzyme Type - Percentage Breakdown of Revenues for Xylanase, Amylase, Cellulase and Others Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-43

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Focus on Reducing Carbon Emissions Drive Strong Demand for Biofuel Enzymes in Biofuel Production III-1 Surging Demand for Biofuels Create Parallel Opportunities for Biofuel Enzymes..............III-1 Table 15: US Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-2 Rising Investments in Next Generation Biofuels Spurs Market Demand.............. III-2 Table 16: The US Biofuel Production by Source (2013, 2016 & 2020): Percentage Share Estimates of Conventional and Advanced (Biomass, Cellulose & Sugarcane) Sources in Biofuel Production (includes corresponding Graph/Chart) III-4 Increasing Fuel Ethanol Production Drives the Need for Biofuel Enzymes..............III-4 Table 17: Fuel Ethanol Production (Million Gallons) in the US: 1980, 1985, 1990, 1995, 2000, 2005, 2010, and 2015E (includes corresponding Graph/Chart) III-5 Favorable Government Mandates Sets the Perfect Platform for Market Penetration..............III-5 Biofuel Blend Mandates & Targets in the US for Major States III-6 Product Launches..............III-6 Strategic Corporate Developments III-7 Select Key Players..............III-8 B.Market Analytics..............III-9 Table 18: US Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-9

Table 19: US Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-10

2. CANADA.............. III-11 A.Market Analysis.............. III-11 Renewable Fuel Standard (RFS) Offers Market Opportunities III-11 Table 20: Canadian Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-11 Corporate Development..............III-12 Iogen Corporation - A Major Canada-Based Company III-12 B.Market Analytics..............III-13 Table 21: Canadian Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-13

Table 22: Canadian Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-14

3. JAPAN.............. III-15 Market Analysis.............. III-15 Table 23: Japanese Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-15

Table 24: Japanese Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-16

4. EUROPE.............. III-17 A.Market Analysis.............. III-17 Outlook.............. III-17 Biofuels Market in Europe: A Macro Perspective III-17 Table 25: European Biofuels (Fuel Ethanol and Biodiesel) Market by Region/Country (2016 & 2020): Breakdown of Volume Consumption in Thousand Gallons for France, Germany, Italy, UK, Spain, Poland, and Rest of Europe (includes corresponding Graph/Chart)..............III-18

Table 26: European Biofuels (Fuel Ethanol and Biodiesel) Market by Type (2016): Percentage Breakdown of Volume Consumption for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart)..............III-18

Table 27: European Biodiesel Production Capacity by Country (2014): Percentage Breakdown of Capacity for Belgium, France, Germany, Greece, Italy, Poland, Spain, The Netherlands and Others (includes corresponding Graph/Chart) III-19 Biofuel Mandates in Europe..............III-19 Demand for Cellulosic Ethanol Gain Momentum, Bodes Well for the Market.............. III-20 B.Market Analytics..............III-21 Table 28: European Recent Past, Current and Future Analysis for Biofuel Enzymes by Geographic Region- France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-21

Table 29: European Historic Review for Biofuel Enzymes Market by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-22

Table 30: European 14-Year Perspective for Biofuel Enzymes by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-23

4a. FRANCE.............. III-24 A.Market Analysis.............. III-24 French Biofuels Market Overview III-24 Table 31: French Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-24 Corporate Development..............III-25 B.Market Analytics..............III-25 Table 32: French Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-25

Table 33: French Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-26

4b. GERMANY.............. III-27 A.Market Analysis.............. III-27 German Biofuel Market: An Overview III-27 Table 34: German Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-28 Germany Mandates Comprehensive Certification and Documentation for BioFuel Sales III-28 Demand for Cellulosic Ethanol Witness Upward Momentum III-28 Corporate Development..............III-29 Select Key Players..............III-29 B.Market Analytics..............III-31 Table 35: German Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-31

Table 36: German Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-32

4c. ITALY.............. III-33 Market Analysis.............. III-33 Table 37: Italian Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-33

Table 38: Italian Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-34

4d. THE UNITED KINGDOM..............III-35 A.Market Analysis.............. III-35 The UK Biomass Energy Sector: An Overview III-35 Table 39: UK Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-35 Enzyme Supplies Limited - A Major UK-Based Company III-36 B.Market Analytics..............III-36 Table 40: UK Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-36

Table 41: UK Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-37

4e. SPAIN.............. III-38 Market Analysis.............. III-38 Table 42: Spanish Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-38

Table 43: Spanish Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-39

4f. RUSSIA.............. III-40 Market Analysis.............. III-40 Table 44: Russia Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-40

Table 45: Russia Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-41

4g. REST OF EUROPE.............. III-42 A.Market Analysis.............. III-42 'Biofuels Obligation Scheme' Boosts Market Prospects in Ireland III-42 Expanding Market for Biofuels in Sweden Augurs Well III-42 Product Launches..............III-42 Corporate Development..............III-43 Select Key Players..............III-43 B.Market Analytics..............III-45 Table 46: Rest of Europe Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-45

Table 47: Rest of Europe Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-46

5. ASIA-PACIFIC.............. III-47 A.Market Analysis.............. III-47 Demand for Biofuel Enzymes Grow Steadily in Asia III-47 Asia-Pacific Biofuels Market: An Overview III-47 Key Trends in a Nutshell..............III-47 Table 48: Asia-Pacific Biofuels (Fuel Ethanol and Biodiesel) Market by Region/Country (2016 & 2020): Breakdown of Volume Consumption in Thousand Gallons for Australia, China, India, Indonesia, South Korea and Rest of Asia-Pacific (includes corresponding Graph/Chart) III-48

Table 49: Asia-Pacific Biofuels (Fuel Ethanol and Biodiesel) Market by Type (2016): Percentage Breakdown of Volume Consumption for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-48 Favorable Policies Support Biofuels Market Growth III-49 Maintaining Agricultural Sustainability: A Key Challenge III-49 Long Pay-Back Period: Another Major Impediment III-49 B.Market Analytics..............III-50 Table 50: Asia-Pacific Recent Past, Current and Future Analysis for Biofuel Enzymes by Geographical Region - China, India and Rest of Asia-Pacific Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-50

Table 51: Asia-Pacific Historic Review for Biofuel Enzymes Market by Geographical Region - China, India and Rest of Asia-Pacific Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-51

Table 52: Asia-Pacific 14-Year Perspective for Biofuel Enzymes by Geographic Region - Percentage Breakdown of Revenues for China, India and Rest of Asia-Pacific Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. III-52

5a. CHINA.............. III-53 A.Market Analysis.............. III-53 Chinese Biofuel Market on a Growth Trajectory III-53 China Aims to Emerge as Major Provider of Second Generation Biofuels.............. III-53 China Promotes Non-Food Sources for Producing Biofuel III-53 Table 53: China Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-54 B.Market Analytics..............III-55 Table 54: China Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-55

Table 55: China Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-56

5b. INDIA.............. III-57 A.Market Analysis.............. III-57 Indian Biofuel Market Driven by the Need to Achieve Energy Security.............. III-57 The National Policy on Biofuels: Goals and Vision III-57 Second-Generation Biofuels Offer High Potential III-59 Table 56: India Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-60 Corporate Development..............III-60 Select Key Players..............III-60 B.Market Analytics..............III-61 Table 57: India Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-61

Table 58: India Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-62

5c. REST OF ASIA-PACIFIC..............III-63 A.Market Analysis.............. III-63 Select Regional Markets..............III-63 Australia: Growing Prominence of Green Fuel III-63 Indonesia: Biofuel Usage Mandates and Production III-63 Market Challenges..............III-64 South Korea: Government Mandates Biodiesel Blending III-64 Philippines: Coconut being Popularized as a Feedstock for Biodiesel.............. III-64 B.Market Analytics..............III-65 Table 59: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-65

Table 60: Rest of Asia-Pacific Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-66

6. LATIN AMERICA.............. III-67 A.Market Analysis.............. III-67 Latin American Biofuels Market Overview III-67 BioDiesel Production Gathers Steam III-67 Biofuel Blending Mandates in Latin America III-68 Table 61: Latin America Biofuels (Fuel Ethanol and Biodiesel) Market by Region/ Country (2016 & 2020): Breakdown of Volume Consumption In Thousand Gallons for Brazil and Rest of Latin America (includes corresponding Graph/Chart).............. III-68

Table 62: Latin America Biofuels (Fuel Ethanol and Biodiesel) Market by Type (2016): Percentage Breakdown of Volume Consumption for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-69 B.Market Analytics..............III-69 Table 63: Latin America Recent Past, Current and Future Analysis for Biofuel Enzymes by Geographical Region- Brazil and Rest of Latin America Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-69

Table 64: Latin America Historic Review for Biofuel Enzymes Market by Geographical Region - Brazil and Rest of Latin America Markets Analyzed with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-70

Table 65: Latin America 14-Year Perspective for Biofuel Enzymes by Geographic Region - Percentage Breakdown of Revenues for Brazil and Rest of Latin America Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. III-71

6a. BRAZIL.............. III-72 A.Market Analysis.............. III-72 Brazil: A Major Producer of Biofuels III-72 Table 66: Brazil Biofuels (Fuel Ethanol and Biodiesel) Market by Product Type (2016 & 2020): Breakdown of Volume Consumption (in '000 Gallons) for Fuel Ethanol and Biodiesel (includes corresponding Graph/Chart) III-73 US Mandate to Increase Biofuel Utilization Helps Brazilian Ethanol Producers..............III-73 Corporate Development..............III-74 B.Market Analytics..............III-74 Table 67: Brazil Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-74

Table 68: Brazil Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-75

6b. REST OF LATIN AMERICA..............III-76 Market Analysis.............. III-76 Table 69: Rest of Latin America Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) III-76

Table 70: Rest of Latin America Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-77

7. REST OF WORLD.............. III-78 A.Market Analysis.............. III-78 Product Launch.............. III-78 TransBiodiesel Ltd. - A Key Israel-based Company III-78 B.Market Analytics..............III-79 Table 71: Rest of World Recent Past, Current and Future Analysis for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-79

Table 72: Rest of World Historic Review for Biofuel Enzymes Market with Annual Revenues in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) III-80

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 24 (including Divisions/Subsidiaries - 25)

The United States (11) Canada (1) Europe (9) - Germany (4) - The United Kingdom (1) - Rest of Europe (4) Asia-Pacific (Excluding Japan) (3) Middle East (1) Read the full report: http://www.reportlinker.com/p04707128-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biofuel-enzymes---biotechnology-300410406.html

SOURCE Reportlinker

http://www.reportlinker.com

See the article here:
Global Biofuel Enzymes - Biotechnology - PR Newswire - PR Newswire (press release)

With five U.S. patents issued and dozens more filed and pending around the world, On Target Laboratories LLC is working to advance its revolutionary fluorescent imaging technology that could help surgeons pinpoint and remove more cancerous tissues than has ever been possible while preserving more healthy tissue for patients.

Headquartered at Purdue Research Park of West Lafayette, the company is developing a series of molecules, which, when administered intravenously, show promise in targeting many types of cancer cells, said Dr. Sumith Kularatne, On Targets vice president of research and development.

In addition to our current U.S. patents, we have 11 more either filed or pending in the U.S., Kularatne said. We have another 33 patents pending worldwide. These patents are very important in helping us move our discoveries to the public where they can help people.

These molecules carry a fluorescent dye and target diseased cells, including cancer, enabling surgeons to better diagnose and remove the disease while avoiding collateral damage to healthy tissue such as nerves.

OTL38 is a novel compound consisting of a folic acid-targeting molecule, or ligand, linked to a near-infrared dye. Following current clinical trial protocols, OTL38 is injected two hours before surgery and is intended to bind to diseased tissue, including several cancers, involving lung, ovarian, and renal. The goal of this technology is to allow the surgeon to see hard-to-detect, small cancer lesions or diseased lymph nodes that might otherwise be missed through the use of a NIR (near-infrared) camera. OTL ligands are designed to enhance the view in real time, and if proven successful, we believe may be an important addition to image-guided surgery.

We have a very robust portfolio of intellectual property (IP), said Martin Low, the companys chief executive officer. We believe, with this proprietary technology, we will enable surgeons in removing any solid tumor cancer.

In addition to cancer, On Target technology has shown promise in targeting infectious diseases and inflammatory diseases.

One of the patents issued for OTL38, On Targets primary molecule, is for the targeting of inflammatory diseases. Another pending patent is for the targeting of some infectious diseases.

In addition to OTL38, On Targets other molecules include: OTL78 which has four patents pending. Its shown promise for prostate, brain, liver, breast and colorectal cancers. OTL81 which has a pending patent. Its shown promise for gastric and thyroid cancers. OTL338 which has a pending patent. Its shown promise for pancreatic, colorectal and kidney cancers as well as tumors under hypoxic conditions. OTL228 which has three patents pending. Its shown promise for ovarian, lung, breast, pituitary and other cancers as well as rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.

On Targets patenting process has moved very quickly due to the strength of the science involved as well as the level of communication between the science and legal teams, Kularatne said.

Normally the patenting process can take years. But our initial five patents were issued in two years, Low said. Pending completion of clinical trials, commercialization of OTL38 for ovarian cancer patients is scheduled for early 2019 and for lung cancer patients in 2021.

While we are working to protect our IP, the real goal here is to save lives, Kularatne said. Cancer may start the fight. We want to finish it.

Link:
Flourescent biotechnology for high lighting solid cancer for more complete surgical removal - Next Big Future

BEIJING, ITHACA, N.Y. and MONTLUON,France, Feb. 25, 2020 /PRNewswire/ -- Advion Inc. today announces parent company Beijing Bohui Innovation Biotechnology Co., Ltd., has filed its intention to acquire Adchim SAS, the parent company of the Interchim group companies. This transaction will subsequently result in the combination of Bohui's subsidiary Advion Inc., a leader in high performance, small footprint mass spectrometry and Interchim SA, a global provider of chromatography and purification instrumentation and consumables for life sciences, research and industry. Building upon seven years of a successful OEM partnership, the companies' future elevated multinational combination for sales of instruments, consumables and customer service is expected to rapidly grow revenue.The combined suite of solutions will be displayed at global conferences beginning in early March, though each company will sustain direct customer transaction relationships until the subsequent combination.

Advion, Inc.s parent company, Bohui Innovation Biotechnology, will acquire the Interchim group and subsequently combine with Advion. Global commercial combination and impact should be notable.

The boards of both companies have agreed to the transaction, which remains contingent upon regulatory approvals and other customary matters.

Complementing Advion's strong academic, pharma, biopharmaceutical and clinical position in mass spectrometry and chromatography products, Interchim adds a broad range of flash chromatography, preparative LC systems, SPE, evaporation, chromatography columns and consumables to the company's combined product portfolio. Partners since 2012, Advion and Interchim led the market by being the first to develop integrated Flash-MS and seamlessly coupling Advion's high performance expression Compact Mass Spectrometer with Interchim's puriFlash chromatography systems. In the future, the combined companies will strengthen the integration and breadth of workflow solutions by adding Advion's proprietary range of novel sample introduction and assay techniques.

In addition to enhanced product integration, the future combination will offer a single source for all instrumentation, column chromatography, sample prep, and consumables sales. Coupled with complementary geographical and market segment strengths, the eventual combination will drive synergistic growth of both companies.

"We are thrilled to combine with Interchim," said David B. Patteson, who will lead the forthcoming combined Bohui Instrument Group. "Our expanded solution deck and global scale will provide a formidable platform for growth offering novel media, columns, prep LC, HPLC, flash chromatography, mass spectrometry, sample prep, and much more. Our customers will benefit from an expanded workflow solution portfolio. Interchim's exceedingly strong Central EU market share and presence, coupled with their dynamic chromatography column business is a perfect commercial fit with Advion's LC/CMS offering.Together with Interchim, we have built strong relationships which persist to this day."

"We are really excited about the perspective of this strategic combination," said Lionel Boch, Prsident du Directoire Interchim. "As a guarantee of a promising future, it represents today for Interchim, its employees, suppliers and partners a perfect fit. The strengths of the two entities, already working together successfully, will be enhanced by this new step and will enable us to reach and develop unparalleled scientific solutions and technological platforms for our customers around the world."

Story continues

Customers and industry partners will benefit from this increased solutions portfolio and can expect significant new developments in mass spectrometry, flash and preparative chromatography of small and large molecules over the course of 2020.

About Advion, Inc.Advion's nearly three-decade dedicationtoserving scientists yields customer-focused lifesciencesolutions. Our deep scientific, engineering and customer workflow knowledge spawns an unrivaled solution portfolio.We work directly with, train, and passionately advocate for our customerstoensure their success.DedicatedtoScienceDedicatedtoYou. More about Advion, Inc. can be found on our website, http://www.advion.com.

About InterchimInterchim SA is a French multinational company dedicated to Sciences with its own R&D laboratory. Founded in 1970, the company has 50 years of experience and knowledge in the field of synthesis, life sciences, as well as analysis and purification by LC chromatography. Our products and services are today available in 60 countries throughour direct sales, subsidiaries and distributors network. For more, visit http://www.interchim.com and http://www.flash-chromatography.com .

View original content to download multimedia:http://www.prnewswire.com/news-releases/advion-incs-parent-company-bohui-innovation-biotechnology-will-acquire-the-interchim-group-and-subsequently-combine-with-advion-global-commercial-combination-and-impact-should-be-notable-301010111.html

SOURCE Advion BioSciences, Inc.

See the rest here:
Advion, Inc.'s parent company, Bohui Innovation Biotechnology, will acquire the Interchim group and subsequently combine with Advion. Global...

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016, posting a loss of more than 20%, has started posting gains again, and is looking like the rally may be poised to continue. The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (NYSEARCA:XBI), is up over 17%).

The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to "speed the approval of life-saving medications" and "cutting the red tape at the FDA." That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.

One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (NYSE:BMY). A StreetInsider article from this week called the company "in play" and listed Roche (OTCQX:RHHBY), Novartis (NYSE:NVS), Gilead (NASDAQ:GILD) and Pfizer (NYSE:PFE) all as potential buyers. Acadia Pharmaceuticals (NASDAQ:ACAD) could also be up for grabs with Biogen (NASDAQ:BIIB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgen's (NASDAQ:AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions, both big and small.

Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73, down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?

From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.

I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.

Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasn't seen in several years.

Gilead's results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (NASDAQ:CELG), Illumina (NASDAQ:ILMN) and Vertex Pharmaceuticals (NASDAQ:VRTX) - all top 10 holdings in the fund - popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read more:
This Biotech ETF Looks Primed To Rally Again - Seeking Alpha

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Monday February 20 as shares jumped 7.76% to close at $40.25. About 1.38 million shares traded hands on 9,993 trades for the day, compared with an average daily volume of 932,251 shares out of a total float of 36.82 million. After opening the trading day at $37.25, shares of Puma Biotechnology Inc stayed within a range of $40.50 to $36.70.

With today's gains, Puma Biotechnology Inc now has a market cap of $1.48 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $34.44 and a 200-day SMA of $41.65.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

See original here:
Puma Biotechnology Inc (PBYI) Soars 7.76% on February 20 - Equities.com

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the long term shareholders of GeneFerm Biotechnology Co., Ltd. (GTSM:1796) have had an unfortunate run in the last three years. Regrettably, they have had to cope with a 63% drop in the share price over that period. And over the last year the share price fell 40%, so we doubt many shareholders are delighted. There was little comfort for shareholders in the last week as the price declined a further 2.0%.

See our latest analysis for GeneFerm Biotechnology

Because GeneFerm Biotechnology made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over the last three years, GeneFerm Biotechnologys revenue dropped 11% per year. That is not a good result. The share price decline of 28% compound, over three years, is understandable given the company doesnt have profits to boast of, and revenue is moving in the wrong direction. Of course, its the future that will determine whether todays price is a good one. Wed be pretty wary of this one until it makes a profit, because we dont specialize in finding turnaround situations.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Its fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of GeneFerm Biotechnology, it has a TSR of -60% for the last 3 years. That exceeds its share price return that we previously mentioned. And theres no prize for guessing that the dividend payments largely explain the divergence!

The last twelve months werent great for GeneFerm Biotechnology shares, which cost holders 39% , including dividends , while the market was up about 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. The three-year loss of 27% per year isnt as bad as the last twelve months, suggesting that the company has not been able to convince the market it has solved its problems. Although Warren Buffett famously said he likes to buy when there is blood on the streets, he also focusses on high quality stocks with solid prospects. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example GeneFerm Biotechnology has 4 warning signs (and 2 which make us uncomfortable) we think you should know about.

Of course GeneFerm Biotechnology may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on TW exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Continue reading here:
Introducing GeneFerm Biotechnology (GTSM:1796), The Stock That Slid 63% In The Last Three Years - Simply Wall St

(MENAFN - Ameliorate Solutions)

The report presents an in-depth assessment of the Global Red Biotechnology including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Red Biotechnology investments from 2020 till 2025.

Industry Overview-

The Red Biotechnology Market is expected to register a CAGR of 5.7% during the forecast period. Red biotechnology is a process that utilizes organisms to improve health and helps the body to fight against diseases. Red biotechnology has become a very important part of the field of diagnostics, gene therapy, and clinical research and trials. Genetic engineering and the development and production of various new medicinal products to treat life-threatening diseases are also part of the benefits of red biotechnology. Severe Combined Immune Deficiency (SCID) and Adenosine deaminase (ADA) deficiency are genetic disorders that were successfully treated with gene therapy. Several promising gene therapies are under development for the treatment of cancer and genetic disorders. According to the World Health Organization (WHO), approximately 6,000 to 8,000 rare diseases found and out of them, nearly 80% are genetic disorders. Rising incidence and prevalence of chronic and rare diseases and increased funding in the healthcare industry are the key driving factors in the red biotechnology market.

Click the link to get a free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/01091744865/red-biotechnology-market-growth-trends-and-forecast-2020-2025/inquiry?Mode=21

Top Leading Manufactures-

Pfizer Inc, AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc, Amgen Inc, Gilead Sciences Inc, Merck KGaA, CSL Limited

Biopharmaceutical Industry Segment is Expected to Hold a Major Market Share in the Red biotechnology Market

- Biopharmaceuticals are medical drugs that are produced by using biotechnology. Biopharmaceuticals are proteins, antibodies, DNA, RNA or antisense oligonucleotides used for therapeutic or diagnostic purposes, and these products are produced by means other than direct extraction from a native (non-engineered) biological source.- The first biopharmaceutical product approved for therapeutic use was recombinant human insulin (Humulin), which was developed by Genentech and marketed by Eli Lily in the year 1982 and in the year 2019, Novartis received FDA approval for gene therapy product in the treatment of spinal muscular atrophy (SMA) condition. Using an AAV9 viral vector, called Zolgensma, which delivers SMN protein into the motor neurons of afflicted patients.- According to the World Health Organization (WHO), globally Cancer is the second leading cause of death and an estimated 9.6 million deaths in the year 2018.- Increasing incidence and prevalence of chronic and rare diseases and rapid expansion of the biopharmaceutical industries are the key driving factors in the biopharmaceutical industry segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global red biotechnology market due to the rising prevalence of chronic and rare diseases, increased expenditure in the healthcare industry in this region. According to the National Institutes of Health (NIH), in the year 2019, approximately 1.8 million people will be diagnosed with cancer in the United States and estimated 268,600 women and 2,670 men will be diagnosed with breast cancer. Moreover, the rise in the adoption of advanced technologies in gene therapy and increasing investments in research and development is fueling the growth of the overall regional market to a large extent.

Inquire for Discount:

https://www.marketinsightsreports.com/reports/01091744865/red-biotechnology-market-growth-trends-and-forecast-2020-2025/discount?Mode=21

Key Strategic Developments : The study also includes the key strategic developments of the market, comprising R & D, new product launch, M & A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a Global and regional scale.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: Global Red Biotechnology Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter's five forces analysis, feasibility study, and investment return analysis have been used to analyzed the growth of the key players operating in the market.

The research includes historic data from 2014 to 2020 and forecasts until 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Media Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

|

MENAFN18012020007010643ID1099570077

The rest is here:
Red Biotechnology Market Size, Status and Recent Advancements, Forecast 2020 to 2025 - MENAFN.COM

The global "Nanoparticles in Biotechnology and Pharmaceuticals Market" market gives a huge platform for different firms, manufacturers, and organizations, such as, Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire that compete among each other for offering reliable products and satisfactory services to their clients and hold considerable shares over the market. The report also provides evaluated data of the market and its rivals on a global basis.

Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=71531

Furthermore, The report presents a detailed segmentation Fullerenes, Liquid Crystals, Liposomes, Nanoshells, Quantum dots, Superparamagnetic nanoparticles, Market Trend by Application Biotechnology, Pharmaceutical of the global market based on technology, product type, application, and various processes and systems.The Nanoparticles in Biotechnology and Pharmaceuticals market report explains the key growth factors and limitations that remarkably influence the market, and also provides the information about the previous and current status of the Nanoparticles in Biotechnology and Pharmaceuticals market at global level.

The global Nanoparticles in Biotechnology and Pharmaceuticals market report incorporates an upcoming estimated impact over the market by the new laws and regulations launched by the government. The market report formation requires detailed research and analysis to realize the market growth; and different scientific strategies, including SWOT analysis to get the information suitable to evaluate the upcoming monetary variations associated to the current situation and growth pattern of the market.

Read Detailed Index of full Research Study at:: https://www.reportsbuzz.com/71531/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-outlook/

The global Nanoparticles in Biotechnology and Pharmaceuticals market report offers comprehensive important points that significantly affect the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market at a global level. It gives the present status and also future growth pattern of the market. The report is created after detailed research and exhaustive investigation of the market development in different sectors that requires theoretical analysis, technology-based ideas, and its validity. The report includes the description about the factors that considerably enhance and downgrade the growth of the market profound explanation of the market's past data; alongside the current investigated data, and forecast the development trend of the Nanoparticles in Biotechnology and Pharmaceuticals market. The global Nanoparticles in Biotechnology and Pharmaceuticals market report also provides a hypothetical study related to the monetary insecurities about demand and supply.

There are 15 Chapters to display the Global Nanoparticles in Biotechnology and Pharmaceuticals market

Chapter 1, Definition, Specifications and Classification of Nanoparticles in Biotechnology and Pharmaceuticals, Applications of Nanoparticles in Biotechnology and Pharmaceuticals, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Nanoparticles in Biotechnology and Pharmaceuticals, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Nanoparticles in Biotechnology and Pharmaceuticals Segment Market Analysis (by Type);Chapter 7 and 8, The Nanoparticles in Biotechnology and Pharmaceuticals Segment Market Analysis (by Application) Major Manufacturers Analysis of Nanoparticles in Biotechnology and Pharmaceuticals ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Fullerenes, Liquid Crystals, Liposomes, Nanoshells, Quantum dots, Superparamagnetic nanoparticles, Market Trend by Application Biotechnology, Pharmaceutical;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Nanoparticles in Biotechnology and Pharmaceuticals ;Chapter 12, Nanoparticles in Biotechnology and Pharmaceuticals Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Nanoparticles in Biotechnology and Pharmaceuticals sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.reportsbuzz.com/inquiry-for-buying.html?repid=71531

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

See the original post here:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market Insights, Growth Analysis, Forecasts to 2025 : Roche, GE Healthcare, Merck, Novartis...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Puma Biotechnology, Inc. (NASDAQ:PBYI) for five years would be nursing their metaphorical wounds since the share price dropped 96% in that time. And we doubt long term believers are the only worried holders, since the stock price has declined 68% over the last twelve months. Furthermore, it's down 31% in about a quarter. That's not much fun for holders.

We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

Check out our latest analysis for Puma Biotechnology

Given that Puma Biotechnology didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:PBYI Income Statement, December 6th 2019

This free interactive report on Puma Biotechnology's balance sheet strength is a great place to start, if you want to investigate the stock further.

Puma Biotechnology shareholders are down 68% for the year, but the market itself is up 18%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 48% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See more here:
Those Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It - Yahoo Finance

Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $92.05, down from yesterdays close by -2.23%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.

Fundamental Analysis

Money managers are always interested in a company that can find the right recipe of fundamental data because it reflects something important going on underneath the surface. Puma Biotechnology, Inc. (PBYI) currently trades with a market capitalization of $3.36 Billion.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PBYI, the company currently has $80.82 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $-158.57 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $-2.36 on a per share basis this quarter. Perhaps, that suggests something about why 94.40% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Puma Biotechnology, Inc. recorded a 52-week high of $98.85. It is now trading 6.8% off that level. The stock is trading $87.01 its 50-day moving average by -5.04%. The stock carved out a 52-week low down at $28.35.

In recent action, Puma Biotechnology, Inc. (PBYI) has made a move of +3.20% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 47.04, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 19.78% with $32.23 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PBYI.

See the article here:
Puma Biotechnology, Inc. (PBYI): From Top to Bottom - StockNewsJournal

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events Market Exclusive Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over ... Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017Business Wire (press release) Puma Biotechnology Reports Fourth Quarter and Full Year 2016 ...Yahoo Finance Puma Biotechnology Inc (NYSE:PBYI) Registers a Net Consolidated EPS Of $-7.4483Equities Focus NewsDen all 6 news articles »

See the original post here:
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events - Market Exclusive